Topotecan or other agents as second‑line therapy for relapsed small‑cell lung cancer: A meta‑analysis of randomized studies

Petrelli,Fausto; Ghidini,Antonio; Luciani,Andrea

doi:10.3892/mco.2021.2383

Topotecan or other agents as second‑line therapy for relapsed small‑cell lung cancer: A meta‑analysis of randomized studies

Authors:
- Fausto Petrelli
- Antonio Ghidini
- Andrea Luciani
View Affiliations

Affiliations: Oncology Unit, Medical Sciences Department, Local Social Health District of Bergamo Ovest, I‑24047 Treviglio (BG), Italy, Oncology Unit, Medicine Department, Casa di Cura Igea, I‑20129 Milan, Italy
Published online on: August 25, 2021 https://doi.org/10.3892/mco.2021.2383
Article Number: 218
Copyright: © Petrelli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small cell lung cancer (SCLC) is exceptionally responsive to chemotherapy and radiotherapy. In relapsed patients, particularly in resistant/refractory cases, the progression of disease occurs rapidly with second‑line agents. Topotecan (TOPO), a camptothecin analog, is the only agent able to increase overall survival (OS) compared with the best supportive care alone. However, the efficacy of platinum‑based chemotherapy rechallenge or other agents has not been systematically explored. In the present review, published articles, which evaluated outcome and toxicity associated with TOPO or non‑TOPO‑based chemotherapy in patients with SCLC from inception to September 2020 were systematically searched and identified by searching the PubMed, EMBASE and Cochrane Library databases. The primary outcome of interest was the risk of death (OS), and the secondary endpoints were risk of progression progression‑free survival (PFS), overall response rate (ORR) and G3‑4 hematological toxicities. A total of nine studies were included in quantitative synthesis for a total of 1,689 patients. They included platinum‑based rechallenge, anthracycline‑based combinations or camptothecin analogs. TOPO did not improve OS with respect to other therapies [hazard ratio (HR), 0.92; 95% confidence interval (95% CI), 0.78‑1.09; P=0.33]. Similarly, PFS was similar in the two arms (HR, 1.1; 95% CI, 0.72‑1.67; P=0.66). The ORR was not statistically higher with non‑TOPO agents (relative risk, 1.53; 95% CI, 0.95‑2.48). In subgroup analysis, combination chemotherapy was associated with an improved PFS but not OS or ORR compared with TOPO alone (HR, 1.85; 95% CI, 1.52‑2.24; P<0.01). The rates of G3‑4 anemia, febrile neutropenia and neutropenia were similar. In conclusion, in patients with relapsed SCLC, TOPO was associated with a similar survival, PFS and ORR as other agents. However, polychemotherapy was associated with improved PFS.

View Figures

View References

1	Horn L, Mansfield AS, Szczȩsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 379:2220–2229. 2018.PubMed/NCBI View Article : Google Scholar
2	Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, et al: Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet. 394:1929–1939. 2019.PubMed/NCBI View Article : Google Scholar
3	O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC and Crofts T: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 24:5441–5447. 2006.PubMed/NCBI View Article : Google Scholar
4	Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 17:658–667. 1999.PubMed/NCBI View Article : Google Scholar
5	Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, et al: Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 21:1224–1233. 2020.PubMed/NCBI View Article : Google Scholar
6	Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
7	Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P and Schünemann HJ: GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336:924–926. 2008.PubMed/NCBI View Article : Google Scholar
8	Parmar MK, Torri V and Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 17:2815–2834. 1998.PubMed/NCBI View Article : Google Scholar
9	Von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, et al: Randomized phase III trial of Amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 32:4012–4018. 2014.PubMed/NCBI View Article : Google Scholar
10	Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF and Oliver JW: Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 29:287–293. 2011.PubMed/NCBI View Article : Google Scholar
11	Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et al: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol. 26:5401–5406. 2008.PubMed/NCBI View Article : Google Scholar
12	Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, et al: Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 17:1147–1157. 2016.PubMed/NCBI View Article : Google Scholar
13	Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, Syrigos KN, Shen L, Chadjaa M and Wolf M: Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy. J Thorac Oncol. 10:1221–1228. 2015.PubMed/NCBI View Article : Google Scholar
14	Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, et al: A randomized phase II study of linsitinib (OSI·906) versus topotecan in patients with relapsed small·cell lung cancer. Oncologist. 21:1163–1164. 2016.PubMed/NCBI View Article : Google Scholar
15	Kondo R, Watanabe S, Shoji S, Ichikawa K, Abe T, Baba J, Tanaka J, Tsukada H, Terada M, Sato K, et al: A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology. 94:223–232. 2018.PubMed/NCBI View Article : Google Scholar
16	Trafalis DT, Alifieris C, Stathopoulos GP and Sitaras N: Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol. 77:713–722. 2016.PubMed/NCBI View Article : Google Scholar
17	Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, Gioulbasanis I, Samonis G, Kalbakis K and Georgoulias V: Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemother Pharmacol. 68:63–68. 2011.PubMed/NCBI View Article : Google Scholar
18	Ramalingam SS, Foster J, Gooding W, Evans T, Sulecki M and Belani CP: Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. Cancer. 116:1344–1349. 2010.PubMed/NCBI View Article : Google Scholar
19	Chen G, Huynh M, Fehrenbacher L, West H, Lara PN Jr, Yavorkovsky LL, Russin M, Goldstein D, Gandara D and Lau D: Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 27:1401–1404. 2009.PubMed/NCBI View Article : Google Scholar
20	Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A, Papakotoulas P, Rapti A, Chandrinos V, Christophyllakis C and Georgoulias V: A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer. 65:187–191. 2009.PubMed/NCBI View Article : Google Scholar
21	Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T and Nishio M: Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 61:503–508. 2008.PubMed/NCBI View Article : Google Scholar
22	Rocha-Lima CM, Herndon JE II, Lee ME, Lee ME, Atkins JN, Mauer A, Vokes E and Green MR: Cancer and Leukemia Group B. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902. Ann Oncol. 18:331–337. 2007.PubMed/NCBI View Article : Google Scholar
23	Schuette W, Nagel S, Juergens S, Bork I, Wollschlaeger B, Schaedlich S and Blankenburg T: Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer. 7:133–137. 2005.PubMed/NCBI View Article : Google Scholar
24	Ichiki M, Rikimaru T, Gohara R, Koga T, Kawayama T, Matunami M, Oshita Y, Kamimura T and Aizawa H: Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer. Oncology. 64:306–311. 2003.PubMed/NCBI View Article : Google Scholar